desktop bg

    ASCO GU 2026

    Presentations Supported by Bayer

    February 26-28, 2026

    Agenda of oral and poster presentations at the 2026 Genitourinary (GU) Symposium of the American Society of Clinical Oncology (ASCO).


    Please see below to download a PDF for each presentation and view a video (where applicable). Access for each publication will be available after the congress presentation.

    Please select a compound to navigate to all related publications.

    DAROLUTAMIDE

    desktop listing bg

    Efficacy and safety of darolutamide and ADT in patient subgroups by baseline comorbidities and concomitant medications: ARANOTE
    post hoc
    analyses

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Fred Saad

    Poster Board Number:
    F7

    desktop listing bg

    Analysis of quality-adjusted time without symptoms or toxicity (Q-TWiST) in patients with metastatic hormone-sensitive prostate cancer: From the ARASENS trial

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Brigida Anna Maiorano

    Poster Board Number:
    D14

    desktop listing bg

    Efficacy and safety of darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): 52-week results from ARAMON

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Andrew Laccetti

    Poster Board Number:
    E22

    desktop listing bg

    Real-world darolutamide safety and effectiveness in nonmetastatic castration-resistant prostate cancer (nmCRPC) by lipid-modifying agent use: Post hoc analyses of DAROL interim analysis 4 (IA4)

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Murilo Luz

    Poster Board Number:
    C6

    desktop listing bg

    Androgen-Receptor pAthwAy inhibitors Triplet therapy (ARAAT): Real-world outcomes in metastatic hormone-sensitive prostate cancer

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Alicia K Morgans

    Poster Board Number:
    B15

    desktop listing bg

    Real-world use of novel hormonal therapies in European and North American patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Zdravko Vassilev

    Poster Board Number:
    B19

    desktop listing bg 1070*420

    Impact of hospitalizations on health-related quality of life and overall survival in metastatic castration-sensitive prostate cancer: Insights from the ARANOTE trial

    Date/Time:
    February 27, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session B: Prostate Cancer and Urothelial Carcinoma

    Type:
    Poster

    Presenting Author:
    Alicia K Morgans

    Poster Board Number:
    A16

    desktop listing bg 1070*420

    Safety Profile of Darolutamide + ADT compared to Enzalutamide, Apalutamide, and Abiraterone in metastatic castration-sensitive prostate cancer: Results from the First Safety Matching-Adjusted Indirect Comparison

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Neal Shore

    Poster Board Number:
    D18

    desktop listing bg 1070*420

    Harnessing caregiver support to improve shared decision-making in metastatic prostate cancer treatment: A US-based quantitative survey

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Daniel George

    Poster Board Number:
    D12

    desktop listing bg 1070*420

    Novel androgen receptor inhibitors for the treatment of metastatic castration-sensitive prostate cancer: A cost-effectiveness analysis

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    William V Padula

    Poster Board Number:
    G5

    desktop listing bg 1070*420

    Discontinuation Rates Among Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) initiating novel androgen receptor inhibitors in Oncology and Non-Oncology settings

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Hannus McManus

    Poster Board Number:
    C12

    desktop listing bg 1070*420

    A phase 2 trial of darolutamide to enhance prostate-specific membrane antigen expression in patients with localized prostate cancer (Daro-PET)

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Jose Mauricio Mota

    Poster Board Number:
    K2

    desktop listing bg 1070*420

    Impact of age, number of cycles of chemotherapy and presence of visceral metastases on PSA response in patients on triplet therapy (ADT + Darolutamide + Docetaxel) for mHSPC: UK real world data from the RECOMMEND study

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Amit Bahl

    Poster Board Number:
    A26

    desktop listing bg 1070*420

    3-Weekly Docetaxel 75 mg/m
    2
    vs 2-Weekly Docetaxel 50 mg/m
    2
    in Combination with Darolutamide + ADT in Patients with mHSPC : Subgroup Analyses from the Randomised Phase 3 ARASAFE Trial

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Marc-Oliver Grimm

    Poster Board Number:
    E8

    desktop listing bg 1070*420

    Prognostic significance of depressive symptoms in men with advance prostate cancer (PC): Results from the IRONMAN registry

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Elizabeth Tran

    Poster Board Number:
    D20

    desktop listing bg 1070*420

    Sequencing of therapeutic agents before and after metastatic castration-resistant prostate cancer (mCRPC) diagnosis in an international real-world setting

    Date/Time:
    February 26, 2026 | 11:30 AM -12:45 PM; 5:45 PM - 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Rana R McKay

    Poster Board Number:
    C7

    RADIUM-223

    desktop listing bg 1070*420

    Final Overall Survival Results from the EORTC 1333/PEACE-3 Trial: Enzalutamide With or Without Radium-223 in Metastatic Castration-Resistant Prostate Cancer

    Date/Time:
    February 26, 2026 | 8:15 - 8:25 AM (PST)

    Session:
    Oral Abstract Session A: Prostate Cancer

    Type:
    Oral

    Presenting Author:
    Enrique Gallardo

    Abstract Number:
    15

    desktop listing bg 1070*420

    Long-Term Outcomes With Radium-223 in Metastatic Castration Resistant Prostate Cancer: US Patient Subset of the 10-Year REASSURE Global Study

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Celestia Higano

    Poster Board Number:
    B18

    desktop listing bg 1070*420

    Real-world characteristics of long-term survivors with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): An analysis of the global REASSURE study

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Saby George

    Poster Board Number:
    B7

    desktop listing bg 1070*420

    Genomic profiling in circulating tumor DNA from a multicenter prospective study of radium-223 in bone-metastatic castration-resistant prostate cancer: the KYUCOG-1901 study

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Masaki Shiota

    Poster Board Number:
    H4

    desktop listing bg 1070*420

    Radium 223 without Androgen Deprivation Therapy (ADT) in Patients (Pts) with Biochemically Recurrent Prostate Cancer (BCR) and PET Findings in the Bones

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Melissa L Abel

    Poster Board Number:
    G1

    desktop listing bg 1070*450

    Circulating tumor DNA (ctDNA} dynamics in bone-dominant metastatic castration resistant prostate cancer (mCRPC} treated with radium-223 with or without olaparib: Biomarker analyses from the multicenter, randomized, phase 2, investigator-initiated COMRADE trial

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Rana R. McKay

    Poster Board Number:
    E13

    PIPELINE

    desktop listing bg 1070*420

    First-in-human assessment of actinium-225-prostate-specific membrane antigen (
    225
    Ac-PSMA)-Trillium (BAY 3563254) in mCRPC: Dose-escalation results of the Phase 1 PAnTHa study

    Date/Time:
    February 26, 2026 | 5:00 PM PM – 5:45 PM (PST)

    Session:
    Rapid Oral Abstract Session A: Prostate Cancer

    Type:
    Oral

    Presenting Author:
    Fred Saad

    Abstract
    #19